The implications of anemia in multiple myeloma

Clinical Lymphoma

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Mittelman, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Erythropoietin; Quality of life; Recombinant human erythropoietin; Red blood cell transfusion

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; INTERLEUKIN 1; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOVASCULAR SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DRUG RESPONSE; ERYTHROCYTE APLASIA; ERYTHROPOIESIS; FLU LIKE SYNDROME; HEMATOCRIT; HEMOLYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUTRITIONAL DEFICIENCY; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SKIN IRRITATION;

EID: 0142124313     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.s.005     Document Type: Article

References (70)

1. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50:29-40.
2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330:484-489.
3. Dalton WS, Bergsagel PL, Kuehl WM, et al. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2001:157-177.
4. Anderson KC, Shaughnessy JD, Jr., Barlogie B, et al. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2002:214-240.
5. Samson D. Guideline: diagnosis and management of multiple myeloma. Br J Haematol 2001; 155:522-540.
6. Cline MJ, Berlin NI. Studies of the anemia of multiple myeloma. Am J Med 1962; 33:510-525.
7. Foerster J, Paraskevas F. Multiple Myeloma. In: Lee GR, Foerster J, Lukens J, et al., eds. 10th ed. Wintrobe's Clinical Hematology. Baltimore: Williams & Wilkins, 1999:2631-2680.
8. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia issociated with multiple myeloma. N Engl J Med 1990; 322:1693-1699.
9. Barlogie B, Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 1993; 11:88-94.
10. Mittelman M. Anemia of cancer: pathogenesis and treatment with recombinant erythropoietin. Isr J Med Sci 1996; 32:1201-1206.
11. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994; 84:997-1004.
12. Lee GR. The anemia of chronic disease. Semin Hematol 1983; 20:61-80.
13. Maruyama F, Ezaki K, Okamoto M, et al. Increased blood cell destruction during vigorous regeneration of bone marrow after intensive chemotherapy for non-Hodgkin lymphoma. Eur J Cancer 1993; 29A:1499.
14. Singh A, Eckardt KU, Zimmermann A, et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993; 91:251-256.
15. Kopp WL, MacKinney AA, Jr., Wasson G. Blood volume and hematocrit value in macroglobulinemia and myeloma. Arch Intern Med 1969; 123:394-396.
16. Sears DA. Anemia of chronic disease. Med Clin North Am 1992; 76:567-579.
17. Berlin NI. Anemia of cancer. Ann N Y Acad Sci 1974; 230:209-211.
18. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198-1204.
19. Musto P, Falcone A, D'Arena G, et al. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol 1997; 58:314-319.
20. Beguin Y. Erythropoiesis and erythropoietin in multiple myeloma. Leuk Lymphoma 1995; 18:413-421.
21. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689-1692.
22. Mittelman M, Floru S, Djaldetti M. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Blood 1992; 80:841-843.
23. Beguin Y, Yerna M, Loo M, et al. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992; 82:648-653.
24. Mittelman M. Recombinant erythropoietin in myelodysplastic syndromes: whom to treat and how? More questions than answers. Acta Haematol 1993; 90:53-57.
25. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-4453.
26. Ariad S, Clifford D, Penfold G, et al. Erythropoietin response in anaemic patients with multiple myeloma and other lymphoid malignancies infiltrating the bone marrow. Eur J Haematol 1992; 49:59-62.
27. Aoki I, Nishijima K, Homori M, et al. Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin in vitro in multiple myeloma. Br J Haematol 1992; 81:463-469.
28. Spivak JL, Pham T, Isaacs M, et al. Erythropoietin is both a mitogen and a survival factor. Blood 1991; 77:1228-1233.
29. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34(suppl 2):13-19.
30. Mittelman M, Zeidman A, Fradin Z, et al. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 1997; 98:204-210.
31. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15:1218-1234.
32. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16:3412-3425.
33. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14:511-519.
34. Piper B. Alterations in energy: the sensation of fatigue. In: Baird S, McCorkle R, Grant M, et al, eds. Cancer nursing: a comprehensive textbook. Philadelphia: Saunders, 1991:894-908.
35. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775-1780.
36. Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996; 201:553-558.
37. Shasha D. The negative impact of anemia on radiotherapy and chemoradiation outcomes. Semin Hematol 2001; 38(suppl 7):8-15.
38. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-852.
39. Silver RT. New approaches to the treatment of cancer-related anemia: Introduction. Semin Oncol 1994; 21(suppl 3):1-2.
40. Klein HG. Immunologic aspects of blood transfusion. Semin Oncol 1994; 21(suppl 3):16-20.
41. Cremieux PY, Barrett B, Anderson K et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000; 18:2755-2761.
42. Krantz SB. Erythropoietin. Blood 1991; 77:419-434.
43. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324:1339-1344.
44. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 82:7580-7584.
45. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321:158-163.
46. Ludwig H, Leitgeb C, Fritz E, et al. Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer 1993; 29A(suppl 2):S8-S12
47. Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 1995; 155:2069-2074..
48. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996; 87:2675-2682.
49. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113:172-179.
50. Pescherstorfer M, Schmoranzer F, Vesley M, et al. Erythropoietin beim multiplen myeloma (erythropoietin in multiple myeloma). Dtsch Med Wschr 1990; 115:1096-1099.
51. Molica S. Erythropoietin treatment of anaemia associated with lymphoproliferative disorders. Eur J Cancer 1993; 29A:1499-1500.
52. Bessho M, Hirashima K, Tsuchiya J. Improvement of anemia in patients with multiple myeloma by recombinant erythropoietin: A multicenter study. Exp Hematol 1994; 22:705.
53. Adam Z, Krahulova M, Spelda S, et al. Therapy of anemia in patients with multiple myeloma. Acta Med Austriaca 1995; 22:59-64.
54. Silvestris F, Romito A, Fanelli P, et al. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995; 70:313-318.
55. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
56. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-1063.
57. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89:4248-4267.
58. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100:2303-2320.
59. Musto P. The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma. Leuk Lymphoma 1998; 29:283-291.
60. Mittelman M, Lessin LS. Clinical application of recombinant erythropoietin in myelodysplasia. Hematol Oncol Clin North Am 1994; 8:993-1009.
61. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469-475.
62. Bunn HF. Drug-induced autoimmune red-cell aplasia. N Engl J Med 2002; 346:522-523.
63. Adamson JW. The relationship of erythropoietin and iron metabolism to red blood cell production in humans. Semin Oncol 1994; 21(2 suppl 3):9-15.
64. National Health Services Executive. Better Blood Transfusion. Wetherby, England: Dept of Health; Dec 11, 1998. HSC 1998/224.
65. Mittelman M, Zeidman A, Fradin Z, et al. Erythropoietin has an antimyeloma effect-A clinical observation supported by animal studies. Blood 2002; 100(suppl):391b.
66. Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001; 98:5181-5186.
67. Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4:161-167.
68. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-2882.
69. Okuno Y, Takahashi T, Suzuki A, et al. Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 1990; 170:1128-1134.
70. Rogers S, Russell NH, Morgan AG. Effect of erythropoietin in patients with myeloma. BMJ 1990; 301:667.